Posts with tag: drums
Medical device company ResMed (NYSE:RMD) beat revenue and EPS estimates for Q4, posting $1.28 billion in revenue and $2.43 in non-GAAP EPS. Despite strong growth in sleep and breathing health products, the stock dropped. Read the full research report for analysis of ResMed's financials and market outlook.
Published on: January 31, 2025, 09:00 PM UTC